10-Q: Skinvisible Inc. Q1 2026 Financials Show Persistent Net Loss

Skinvisible Inc. reported a net loss of $267,184 for the first quarter of 2026, with revenues remaining flat at $5,000, while operating expenses decreased slightly.

Summary

• Skinvisible, Inc. reported a net loss of $267,184 for the three months ended March 31, 2026, compared to a net loss of $281,005 for the same period in 2025.
• Total revenues remained flat at $5,000 for both the three months ended March 31, 2026, and March 31, 2025.
• Operating expenses decreased to $130,938 in Q1 2026 from $144,852 in Q1 2025, primarily due to a reduction in selling, general, and administrative expenses.
• The company has a significant accumulated deficit of $41,277,360 as of March 31, 2026, and a working capital deficit of $5,252,591.
• Management continues to express substantial doubt about the company's ability to continue as a going concern, citing the need for additional financing and operational success.
• The company is pursuing licensing of its core products and seeking additional debt and equity funding to continue operations.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the persistent net loss, minimal revenue, significant accumulated deficit, and ongoing going concern issues, despite some positive developments in licensing and clinical trials.

Positives

• Operating expenses decreased by approximately 9.6% to $130,938 in Q1 2026 from $144,852 in Q1 2025.
• The company has a license agreement with Quoin Pharmaceuticals for its QRX003 product, which has received Orphan Drug Designation in Europe and Rare Pediatric Disease Designation in the US, and Fast Track Designation from the FDA.
• Quoin Pharmaceuticals is advancing clinical trials for QRX003 for Netherton Syndrome, with positive initial data and a clean safety profile reported.
• The FDA indicated that a single Phase 3 study may be sufficient to support marketing approval for QRX003, potentially expediting the regulatory process.
• The company has filed provisional patent applications for formulations leveraging Invisicare for the transdermal administration of obesity drugs and glucose-controlling agents.

Negatives

• The company reported a net loss of $267,184 for the three months ended March 31, 2026.
• Revenues remain minimal at $5,000 for the quarter, unchanged from the prior year.
• The company has a substantial accumulated deficit of $41,277,360 as of March 31, 2026.
• A working capital deficit of $5,252,591 exists as of March 31, 2026.
• Management has identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties and insufficient written policies and procedures.
• The company's ability to continue as a going concern is subject to substantial doubt due to its history of losses and need for future financing.

Risks

• Uncertainty of profitability based upon the company's history of losses.
• Risks related to failure to obtain adequate financing on a timely basis and on acceptable terms to continue as a going concern.
• Uncertainty with respect to intellectual property rights, protecting those rights and claims of infringement of others' intellectual property.
• Competition in the skincare, dermatology, and pharmaceutical markets.
• Cybersecurity concerns.
• The success of the company's business model relies heavily on licensing agreements and the ability to secure future financing, which is not guaranteed.
• The remediation of material weaknesses in internal control over financial reporting is dependent on securing additional financing.

Future Outlook

The company hopes to generate more revenues from its licenses with Quoin and Ovation in 2026 and plans to enter into commercial arrangements with pharma and biotech companies to exploit its recent patent applications. Management expects operating expenses to increase as licensing revenue grows. The company intends to seek additional financing in a private equity offering to fund operations, but success is not assured.

Management Comments

• "The Company has incurred cumulative net losses of $41,277,360 since its inception and requires capital for its contemplated operational and marketing activities to take place."
• "Managements plans for the Company are to generate the necessary funding through licensing of its core products and to seek additional debt and equity funding."
• "The obtainment of additional financing, the successful development of the Companys contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations."
• "Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months."
• "There can be no assurance that we will be successful in raising additional capital."

Industry Context

StockSavvy.ai notes that Skinvisible's focus on topical and transdermal delivery systems aligns with broader trends in the pharmaceutical and skincare industries seeking innovative delivery methods to enhance efficacy and reduce side effects. The company's efforts in areas like obesity and diabetes management through transdermal delivery are targeting significant and growing markets.

Comparison to Industry Standards

• Skinvisible's revenue of $5,000 for the quarter is exceptionally low compared to established pharmaceutical or skincare companies, which typically generate millions or billions in quarterly revenue.
• The company's net loss of $267,184 and accumulated deficit of over $41 million are significant, indicating a long path to profitability, which is not uncommon for early-stage R&D companies but requires substantial ongoing investment.
• The progress of Quoin Pharmaceuticals' QRX003 for Netherton Syndrome, including FDA designations (Fast Track, Orphan Drug, Rare Pediatric Disease), suggests potential for a novel therapeutic, but the ultimate market success and revenue generation remain to be seen.
• The company's business model relies on licensing, a common strategy in the biotech and pharma sectors, but success is contingent on securing strong partners and achieving regulatory milestones, as seen with the Quoin and Ovation Science agreements.

Corporate Governance

Related Party Transactions

• Loans from related party totaled $61,544 as of March 31, 2026, an increase from $45,044 as of December 31, 2025.
• Convertible notes payable related party amounted to $5,372,403 as of March 31, 2026, unchanged from December 31, 2025.
• On January 31, 2023, accrued salaries, vacation, and outstanding convertible notes for two officers totaling $4,220,209, $1,062,000, and $90,193 respectively, were converted to promissory notes convertible into common stock with a warrant feature.

Stakeholder Impact

• Shareholders: Continued dilution risk if equity financing is pursued, and ongoing concern about the company's ability to achieve profitability and a positive return on investment.
• Creditors: The company's significant liabilities and working capital deficit raise concerns about its ability to meet its obligations.
• Employees: Potential uncertainty regarding job security due to the going concern status and reliance on future financing for operational stability and remediation efforts.
• Partners (e.g., Quoin, Ovation): Continued reliance on the success of their respective product development and commercialization efforts for revenue generation.

Next Steps

• Continue to pursue licensing of core products.
• Seek additional debt and equity funding.
• Implement remediation plan for material weaknesses in internal control over financial reporting, contingent on securing financing.
• Advance clinical trials for QRX003 (via Quoin Pharmaceuticals) towards potential FDA approval.
• Pursue strategic partnerships for transdermal obesity and glucose-controlling therapies.

Key Dates

Recommendation

While the company shows progress in its licensing agreements and clinical development for QRX003, the persistent net losses, significant accumulated deficit, and explicit statement of doubt regarding its ability to continue as a going concern warrant caution. The company's financial health remains precarious, and its future is heavily dependent on securing substantial additional financing. Investors should hold positions while monitoring the success of financing efforts and the progression of key licensing agreements.

Keywords

Skinvisible, 10-Q, Quarterly Report, Invisicare, Topical Delivery System, Pharmaceutical R&D, Netherton Syndrome, QRX003, Quoin Pharmaceuticals, Ovation Science, DermSafe, Obesity Treatment, Diabetes, Financial Statements, Net Loss, Going Concern